Privately-held CaroGen Corporation has agreed with the National Institute of Allergy and Infectious Diseases, part of the NIH, to provide its AVIDIO-based recombinant influenza vaccine candidates for preclinical evaluation against multiple strains of influenza. The NIAID/NIH is wholly funding this project.